The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.
[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; AKT activator SC79 inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein]
[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]
[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]
[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]
[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]
[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]; AKT activator SC79 inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]
[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]
[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; [FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; [idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]; AKT activator SC79 inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; AKT activator SC79 inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; AKT activator SC79 inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]
[Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; FAS protein affects the reaction [idelalisib results in increased expression of ALT protein] idelalisib affects the expression of GPT protein
idelalisib results in increased expression of HIF1A protein idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of HIF1A protein]
idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA] idelalisib results in decreased expression of MMP9 protein
idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein] idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein]; idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of MTOR mRNA]
idelalisib results in increased expression of PIK3CA mRNA idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]
idelalisib results in increased expression of PIK3CB mRNA idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]
idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA] idelalisib results in increased expression of PIK3CD mRNA
AKT activator SC79 inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]
idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]
idelalisib results in increased susceptibility to TNF protein [TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]
idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA] idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]; idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA protein]